Role of Immunomodulatory Drugs and Proteasome Inhibitors in the Treatment of Myeloma Bone Disease: Literature of Review

International Journal of Medical Science

© 2016 by SSRG - IJMS Journal

Volume 3 Issue 7

Year of Publication : 2016

Authors : Dr. Lohit kumar Kalita, Dr. Mridul Sarma and Dr. Umesh Ch. Sarma

10.14445/23939117/IJMS-V3I7P101

How to Cite?

Dr. Lohit kumar Kalita, Dr. Mridul Sarma and Dr. Umesh Ch. Sarma, "Role of Immunomodulatory Drugs and Proteasome Inhibitors in the Treatment of Myeloma Bone Disease: Literature of Review," SSRG International Journal of Medical Science, vol. 3,  no. 7, pp. 1-6, 2016. Crossref, https://doi.org/10.14445/23939117/IJMS-V3I7P101

Abstract:

 Multiple myeloma (MM) is a clonal plasma cell malignancy, characterized by the proliferation of neoplastic plasma · cells. Currently, with an improved understanding of the genetic as well as biological abnormalities that are a hallmark of multiple myeloma, cytogenetics, and other risk stratification methods are increasingly being proposed to guide the treatment of myeloma. Among others, recent advances have been useful in defining high-risk groups with poor outcome after standard and high-dose chemotherapies. The use of novel agents have improved prognosis for a subset of patients with high-risk disease.

Keywords:

Myeloma, Agents, Immunomodulatory.

References:

[1] Quach H, Ritchie D, Stewart AK, et al. Mechanism 0f action of immunomodulatory drugs (lMiDS) in multiple myeloma. Leukemia. 2010;24:22-32.
[2] Galustian C, Labarthe MC, Bartlett JB et al. Thalidomide-derived immunomodulatory drugs as therapeutic agents. Exp Opin Biolog Ther. 2004;4:1963-70.
[3] Christoulas D, Terpos E, Dimopoulos MA. Pathogenesis and management of myeloma bone disease. Expert Review of Hematology. 2009;2(4):385-98
[4] Terpos E Dimopoulos MA. Myeloma bone disease: Pathophysiology and management. Ann Oncol. 2005;16 (8):1223-31.
[5] Singhal S, Mehta l, Desikan R, et al. Antitumor Activity of Thalidomide in Refractory Multiple Myeloma. N Engl J Med. 1999;341:1565-71.
[6] Schwartz RN, Vozniak M. Current and emerging treatments for multiple myeloma. /Manag Care Pharm. 2008;14(7 Supp|):12-9.
[7] Singhal S, Mehta l, Desikan R, et al. Antitumor Activity of Thalidomide in Refractory Multiple Myeloma. N Engl J Med. 1999;341 :1565-71.
[8] Palumbo A, Facon T, Sonneveld P, et al. Thalidomide for treatment of multiple myeloma: 10 years later. Blood. 2008;111:3968-77.
[9] Yakoub-Agha I, et al. Lower Dose of Thalidomide May Be lust as Effective in Multiple Myeloma abstract). Presented at American Society of Oncology (ASCO) annual meeting, Atlanta, Georgia, June 4, 2006.
[10] Osborn M, Horvath N, To LB. New drugs for multiple myeloma. Aust Prescr. 2009;32:95-8.
[11] Kyle RA, Rajkumar SV. Multiple myeloma. N Engl J Med. 2004,351 :1860-73.
[12] Kyle RA, Rajkumar SV. Multiple myeloma. Blood. 2008,111(6):2962-72.
[13] Rao KV. Lenalidomide in the treatment of multiple myeloma. Am J Health Syst Pharm. 2007;64(1 7):1799-807.
[14] Dimopoulos M, Spencer A, Attal M, et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med. 2007;357:2123-32.
[15] Weber DM, Chen C, Niesvizky R, et al. Lenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North America. N Engl J Med. 2007;357:2133-42.
[16] Roodman GD. Therapeutic Options in Multiple Myeloma: Focus on Bortezomib. Clinical Medicine: Therapeutics. 2009;1 :495-503.
[17] Chauhan D, Hideshima T, Mitsiacles C, et al. Proteasome inhibitor therapy in multiple myeloma. Mol Cancer Ther. 2005;4(4):686-92.
[18] Shah JJ, Orlowski RZ. Proteasome inhibitors in the treatment of multiple myeloma. Leukemia. 2009;23:1964-79.
[19] Adams J, Palombella VJ, Sausville EA, et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res. 1999;59:2615-22.
[20] Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003;348:2609—17.
[21] Laubach JP, Mitsiades CS, Hideshima T, et al. Bortezomib in the management of multiple myeloma. Cancer Management and Research. 2009;1 :107-1 7.
[22] Uy GL, Trivedi R, Peles S, et al. Bortezomib inhibits osteoclast activity in patients with multiple myeloma. Clin Lymphoma Myeloma. 2007;7(9):587—9.
[23] Richardson PG, Barlogie B, Berenson J, et al. A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma. N Engl J Med. 2003;348:2609-17.
[24] Jagannath S, Barlogie B, Berenson J, et al. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol. 2004;127(2):165-72.
[25] Richardson PG, Sonneveld P, Schuster M, et al. Bortezomib or High-Dose Dexamethasone for Relapsed Multiple Myeloma. N Engl J Med. 2005;352:2487-98.
[26] Richardson PG, Sonneveld P, Schuster M, et al. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood. 2007; 110:3557-60.
[27] Ning YM, He K, Dagher R, et al. Liposomal doxorubicin in combination with bortezomib for relapsed or refractory multiple myeloma. Oncology (Williston Park). 2007;21(12):1503-8.
[28] Moreau P, Pylypenko HV, Grosicki S, Karamanesht EE, Leleu X, Grishunina ME, et al. A Phase 3 Prospective Randomized International Study (MMY—3021) Comparing Subcutaneous and Intravenous Administration of Bortezomib In Patients with Relapsed Multiple Myeloma [Abstract 312]. Presented at the 2010 American Society of Hematology. Orlando, Florida.
[29] Kumar S, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008;111:2516-20.
[30] Brenner H, Gondos A, Pulte D. Recent major improvement in long-term survival of younger patients with multiple myeloma. Blood. 2008;111 :2521-6. 
[31] Kumar S, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008;111:2516-20.
[32] Brenner H, Gondos A, Pulte D. Recent major improvement in long-term survival of younger patients with multiple myeloma. Blood. 2008;111 :2521-6.